Ultimately, the most effective screening test is the one a patient completes; clinicians should tailor recommendations to individual preferences to improve uptake.

Blood-based screenings may be easier for patients, with experts and advocacy leaders suggesting potential increases in screening participation and future goals.

The guidance recommends starting screening at age 45 for average-risk adults and continuing to 75, with earlier or more frequent screening for those at increased risk.

If a screening test yields an abnormal result, a follow-up colonoscopy is advised.

The guideline adopts a forward-looking approach to broaden coverage, including younger or underserved populations, acknowledging imperfect sensitivity but prioritizing overall cancer detection and prevention.

Experts say the choice of test should reflect what patients are willing to do, and discussion with a trusted healthcare provider helps tailor the best method.

Shield costs about $895 out of pocket, with insurance coverage hinging on USPSTF recommendations still pending for this test.

Guardant notes the new option targets patients who might otherwise remain unscreened and that these tests are not intended for high-risk individuals.

Guidelines apply to average-risk, asymptomatic individuals without family or personal history of colorectal cancer, and patients should verify insurance coverage for options.

A new blood-based screening option, Shield from Guardant Health, has been added to American Cancer Society guidelines for average-risk adults who can’t or won’t undergo colonoscopy or stool-based tests, expanding choices without replacing more effective methods.

The guidance underscores home-based or in-office testing to lessen barriers like time off work or invasive procedures, aiming to boost early detection and reduce mortality.

The changes reflect advances in detection and a broader push to expand screening options and reduce access barriers.